Przejdź do zawartości
Merck

Characterization of microRNAs differentially expressed during bovine follicle development.

Reproduction (Cambridge, England) (2014-06-13)
Sadanand D Sontakke, Bushra T Mohammed, Alan S McNeilly, F Xavier Donadeu
ABSTRAKT

Several different miRNAs have been proposed to regulate ovarian follicle function; however, very limited information exists on the spatiotemporal patterns of miRNA expression during follicle development. The objective of this study was to identify, using microarray, miRNA profiles associated with growth and regression of dominant-size follicles in the bovine monovular ovary and to characterize their spatiotemporal distribution during development. The follicles were collected from abattoir ovaries and classified as small (4-8  mm) or large (12-17  mm); the latter were further classified as healthy or atretic based on estradiol and CYP19A1 levels. Six pools of small follicles and individual large healthy (n=6) and large atretic (n=5) follicles were analyzed using Exiqon's miRCURY LNA microRNA Array 6th gen, followed by qPCR validation. A total of 17 and 57 sequences were differentially expressed (greater than or equal to twofold; P<0.05) between large healthy and each of small and large atretic follicles respectively. Bovine miRNAs confirmed to be upregulated in large healthy follicles relative to small follicles (bta-miR-144, bta-miR-202, bta-miR-451, bta-miR-652, and bta-miR-873) were further characterized. Three of these miRNAs (bta-miR-144, bta-miR-202, and bta-miR-873) were also downregulated in large atretic follicles relative to large healthy follicles. Within the follicle, these miRNAs were predominantly expressed in mural granulosa cells. Further, body-wide screening revealed that bta-miR-202, but not other miRNAs, was expressed exclusively in the gonads. Finally, a total of 1359 predicted targets of the five miRNAs enriched in large healthy follicles were identified, which mapped to signaling pathways involved in follicular cell proliferation, steroidogenesis, prevention of premature luteinization, and oocyte maturation.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard
Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Imidazole, Molecular Biology, ≥99% (titration), free-flowing, Redi-Dri
Progesterone, European Pharmacopoeia (EP) Reference Standard
Supelco
Imidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Formamide, spectrophotometric grade, ≥99%
Sigma-Aldrich
Formamide, ReagentPlus®, ≥99.0% (GC)
USP
Imidazole, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Imidazole, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Imidazole, ReagentPlus®, 99%
Sigma-Aldrich
Progesterone, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Progesterone, ≥99%
Sigma-Aldrich
Progesterone, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Formamide, ≥99.5% (GC), BioReagent, Molecular Biology
Sigma-Aldrich
Imidazole, ACS reagent, ≥99% (titration)
Sigma-Aldrich
Imidazole, ≥99% (titration), crystalline
Sigma-Aldrich
Imidazole, Molecular Biology, ≥99% (titration)
Sigma-Aldrich
Progesterone, meets USP testing specifications
Sigma-Aldrich
Imidazole, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Imidazole, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
Imidazole, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Formamide, BioUltra, Molecular Biology, ≥99.5% (T)
USP
Progesterone, United States Pharmacopeia (USP) Reference Standard
Supelco
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
Ondansetron impurity E, European Pharmacopoeia (EP) Reference Standard
Supelco
Progesterone, VETRANAL®, analytical standard
Imidazole, European Pharmacopoeia (EP) Reference Standard
Digoxigenin, European Pharmacopoeia (EP) Reference Standard
Supelco
Digoxigenin, analytical standard
Sigma-Aldrich
Imidazole, ReagentPlus®, 99%, Redi-Dri, free-flowing